These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12493134)

  • 1. Oral treatments for type II diabetes in patients with cardiovascular disease.
    Brosnan R
    Cardiol Rev; 2003; 11(1):35-40. PubMed ID: 12493134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.
    Hemmingsen B; Lund SS; Wetterslev J; Vaag A
    Eur J Endocrinol; 2009 Jul; 161(1):1-9. PubMed ID: 19369429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes Mellitus and Its Cardiovascular Complications: New Insights into an Old Disease.
    Sardu C; De Lucia C; Wallner M; Santulli G
    J Diabetes Res; 2019; 2019():1905194. PubMed ID: 31236416
    [No Abstract]   [Full Text] [Related]  

  • 5. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.
    Chi C; Snaith J; Gunton JE
    Heart Lung Circ; 2017 Nov; 26(11):1133-1141. PubMed ID: 28473214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of type 2 diabetes mellitus with oral antihyperglycaemic therapy.
    Desai A; Tandon N
    Natl Med J India; 2007; 20(4):192-8. PubMed ID: 18085125
    [No Abstract]   [Full Text] [Related]  

  • 9. Type 2 diabetes and cardiovascular disease: reducing the risk.
    Bartels DW; Davidson MH; Gong WC
    J Manag Care Pharm; 2007 Mar; 13(2 Suppl A):S2-15; quiz S16-7. PubMed ID: 17330977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
    Bethel MA; Califf RM
    Am J Cardiol; 2007 Mar; 99(5):726-31. PubMed ID: 17317381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.
    Weidman-Evans E; Metz SM; Evans JD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):225-33. PubMed ID: 24490745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F; Cosmi D
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based therapy for type 2 diabetes: A real class effect?
    Savarese G; Lund LH; Rosano GMC
    Int J Cardiol; 2017 Jan; 227():141-142. PubMed ID: 27866064
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus.
    Galla JM; Nicholls SJ
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):85-93. PubMed ID: 19105770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes: Time for reconciliation between cardiologists and diabetologists.
    Scheen AJ
    Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
    [No Abstract]   [Full Text] [Related]  

  • 16. Multifactorial aspects of the treatment of the type II diabetic patient.
    Colwell JA
    Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
    Blonde L; Baker DE; Davis SN; Ratner RE
    J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.